Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|July 20, 2015

Baxter Recalls IV Solution for Insect in Bag

Baxter has initiated a voluntary recall of two lots of IV solutions due to the potential presence of particulate matter.

Baxter International Inc. announced on July 17 that it is voluntarily recalling two lots of intravenous (IV) solutions to the hospital/user level due to the potential presence of particulate matter.

The particulate matter in each case was determined to be an insect and was identified as a result of a customer complaint, the company reports. The matter was identified prior to patient administration and there have been no adverse events associated with this issue reported to Baxter.

This recall affects two lots of 0.9% sodium chloride injection, USP, 50 mL VIAFLEX Plastic Container, a product intended for intravenous use as a source of water and electrolytes. The lots being recalled were distributed to customers and distributors in the United States between Oct. 7, 2014 and July 14, 2015.

Source: Baxter International

 

 


Related to this article

The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.